Robert Duggan (Kelly Morfopoulos via Wikimedia)
October 5, 2020 07:21 AM EDTUpdated 07:52 AM
R&D

With Covid-19 muck­ing the tires, Robert Dug­gan throws an­oth­er $50M be­hind his big an­tibi­otics play

Jason Mast

Editor

Robert Dug­gan is up­ping his ante on Sum­mit Ther­a­peu­tics.

The bil­lion­aire in­vestor qui­et­ly bid up to 65% of the small an­tibi­ot­ic de­vel­op­er be­fore

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times